Findings in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation
WEDNESDAY, Aug. 10, 2016 (HealthDay News) — For patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI), use of a cerebral protection device is associated with a reduction in the frequency of ischemic cerebral lesions, according to a study published in the Aug. 9 issue of the Journal of the American Medical Association.
Stephan Haussig, M.D., from the University of Leipzig in Germany, and colleagues examined the effect of a cerebral protection device on the number and volume of cerebral lesions in patients undergoing TAVI in a single-center randomized trial. Patients with severe aortic stenosis undergoing TAVI underwent brain magnetic resonance imaging at baseline and two and seven days after TAVI. One hundred patients were randomized in a 1:1 ratio to TAVI with a cerebral protection device (filter group) or without a cerebral protection device (control).
The researchers found that the primary end point of the number of new lesions was lower in the filter versus the control group (4.00 versus 10.00; P < 0.001). There was a lower new lesion volume after TAVI in the filter group compared to the control group (527 versus 242 mm³; P = 0.001).
“Larger studies are needed to assess the effect of cerebral protection device use on neurological and cognitive function after TAVI and to devise methods that will provide more complete coverage of the brain to prevent new lesions,” the authors write.
Several authors disclosed financial ties to pharmaceutical and medical device companies, including Claret Medical and Medtronic, which funded the study.
Abstract
Full Text
Editorial (subscription or payment may be required)
Copyright © 2016 HealthDay. All rights reserved.
